Interesting snippets of the news releases. You left this out of March 7 release however, " Robert E. Yates, CEO of Pulse, said, "By restructuring our business, receiving new capital and putting it immediately to work producing product, we will ship enough product to reach a break-even EBITDA for the first time in the month of March." Mr. Yates continued, "With additional capital we will be able to produce and ship even more product in April which would then be our first profitable month. We believe the best path to shareholder value is to continue to put together back to back periods of increased revenue and profit." Guess that never happened for March and we don't have April numbers yet. Not to mention Yates filed an 8K to try and erase that misstep of a news release a few weeks later. It's also very interesting since in the last Q filed, PLSB said they shipped 16k cases of aides and 9k+ of CW. So if you take what Yates said in release about booking 16k cases of aides and 5k cases of CW, then they only sold 4K cases of CW in Jan and feb and 5800 cases of aides in Jan and Feb. That is not a fast track solid company. He also noted profitability in April as clear potential and as he said should be their first profitable month. But we've all read his other news releases and know how it usually turns out. How much more did the company raise in toxic deals? What kind of a dilution factor did he put in? Not to mention the more stringent regulations in place to submit sub penny and penny stocks into an account at a clearing firm. Lots of doubt out there